Begin main content

Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness

Published on: September 25, 2017
Project Number: RC0919-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the clinical effectiveness of pimecrolimus for the treatment of adults with atopic dermatitis?
  2. What is the clinical effectiveness of pimecrolimus for the treatment of adults with seborrheic dermatitis?
  3. What is the clinical effectiveness of pimecrolimus for the treatment of adults with psoriasis?
  4. What is the cost-effectiveness of pimecrolimus for the treatment of adults with atopic dermatitis, seborrheic dermatitis, or psoriasis?

Key Message

In atopic dermatitis, pimecrolimus is superior to vehicle (placebo) in decreasing the severity of the symptoms of the disease and in possibly inducing remission. However, evidence from one randomized controlled trial indicated that maintenance therapy with pimecrolimus was not statistically significantly different than vehicle. Evidence when comparing pimecrolimus to corticosteroid treatment can be conflicting: some studies suggested that pimecrolimus shows no statistically significant differences while others show topical corticosteroids to be superior. Tacrolimus was reported to be superior to pimecrolimus. One economic evaluation indicated that topical corticosteroids are less costly and confer more quality adjusted life-years in atopic dermatitis patients.In seborrheic dermatitis, primecrolimus may be statistically significantly better than vehicle in reducing the severity of seborrheic dermatitis symptoms, but little difference can be seen in the number of treatment success patients. Comparison to corticosteroids showed no statistically significant difference across most comparison, with the exception of the comparison with methylprednisolone in reducing the disease severity index; whereas primecrolimus was statistically significantly superior. No statistically significant difference was found when pimecrolimus was compared to sertaconazole in seborrheic dermatitis. No evidence regarding comparative clinical efficacy of pimecrolimus in patients suffering from psoriasis was found. Also, no cost-effectiveness information for pimecrolimus in seborrheic dermatitis or psoriasis patients was found.

Tags

dermatology, eczema, Elidel, eczema